In the fast paced world of PARP inhibitor approvals in both the setting of maintenance and therapy in ovarian cancer, this panel of experts will assist practitioners to understand how to order germline and somatic testing for BRCA and HRD mutations. Speakers discuss sequencing of PARP inhibitors as well as mitigating side effects. Additionally, they discuss future directions for the use of PARP inhibitors as well as briefly discuss resistance to PARP inhibitors.

Speakers:
Premal Thaker, MD, MS
Washington University in St. Louis Siteman Cancer Center

Mary (“Maggie”) Mullen, MD
Washington University in St. Louis School of Medicine

John Farley, MD, COL, FACOG, FACS
Dignity Health - Cancer Institute, St. Joseph's Hospital and Medical Center

Todd Tillmanns, MD, FACOG
West Cancer Center

Keywords: Ovarian, Ovary, PARP, PARPi, Maintenance therapy, Toxicity, future applications


This is an educational resource produced through collaboration between the Society of Gynecologic Oncology (SGO) and the Association of Community Cancer Centers (ACCC). 

     


This activity is supported by independent medical education grants from AstraZeneca and Merck.